Related references
Note: Only part of the references are listed.Ceftaroline Increases Membrane Binding and Enhances the Activity of Daptomycin against Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus in a Pharmacokinetic/Pharmacodynamic Model
Brian J. Werth et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
In Vitro Pharmacodynamics of Vancomycin and Cefazolin Alone and in Combination against Methicillin-Resistant Staphylococcus aureus
Mao Hagihara et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Synergy between Vancomycin and Nafcillin against Staphylococcus aureus in an In Vitro Pharmacokinetic/Pharmacodynamic Model
Steven N. Leonard
PLOS ONE (2012)
Striking Seesaw Effect between Daptomycin Nonsusceptibility and β-Lactam Susceptibility in Staphylococcus haemolyticus
Carla Vignaroli et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Use of Antistaphylococcal β-Lactams to Increase Daptomycin Activity in Eradicating Persistent Bacteremia Due to Methicillin-Resistant Staphylococcus aureus: Role of Enhanced Daptomycin Binding
Abhay Dhand et al.
CLINICAL INFECTIOUS DISEASES (2011)
Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naive patient-a review of the literature
S. J. van Hal et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2011)
Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure
Peter G. Kelley et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Fluorescence Microscopy Demonstrates Enhanced Targeting of Telavancin to the Division Septum of Staphylococcus aureus
Christopher S. Lunde et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications
Benjamin P. Howden et al.
CLINICAL MICROBIOLOGY REVIEWS (2010)
Development of Reduced Vancomycin Susceptibility in Methicillin-Susceptible Staphylococcus aureus
Satish K. Pillai et al.
CLINICAL INFECTIOUS DISEASES (2009)
Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistants Staphylococcus aureus
Steven N. Leonard et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007)
Michael J. Rybak et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2008)
The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus
PC Appelbaum
CLINICAL MICROBIOLOGY AND INFECTION (2006)
False synergy between vancomycin and β-lactams against glycopeptide-intermediate Staphylococcus aureus (GISA) caused by inappropriate testing methods
FW Goldstein et al.
CLINICAL MICROBIOLOGY AND INFECTION (2004)
Staphylococcus aureus with heterogeneous resistance to vancomycin:: Epidemiology, clinical significance, and critical assessment of diagnostic methods
C Liu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital
M Wootton et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2001)
Combination effect of vancomycin and β-lactams against a Staphylococcus aureus strain, Mu3, with heterogeneous resistance to vancomycin
N Aritaka et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Share Paper
